Event JSON
{
"id": "4213faf58e340c1b6c03c2ac3b291448f54b7a8ef934fa314ae4f480c8772d44",
"pubkey": "bd200f91f5f6f2d94b71e5c179a3291de2d6eb025724518b8f0f1356117e4d21",
"created_at": 1731689553,
"kind": 1,
"tags": [
[
"imeta",
"url https://amicale.net/system/media_attachments/files/113/488/006/233/143/852/original/6ceef2f37150be3a.jpg",
"m image/jpeg"
],
[
"proxy",
"https://amicale.net/@reuters/113488006563942345",
"web"
],
[
"proxy",
"https://amicale.net/users/reuters/statuses/113488006563942345",
"activitypub"
],
[
"L",
"pink.momostr"
],
[
"l",
"pink.momostr.activitypub:https://amicale.net/users/reuters/statuses/113488006563942345",
"pink.momostr"
],
[
"-"
]
],
"content": "Eyenovia to end eye drug study after missing late-stage goal, shares fall https://www.reuters.com/business/healthcare-pharmaceuticals/eyenovia-discontinue-late-stage-study-eye-drug-2024-11-15/?taid=6737712e4785860001be307a\u0026utm_medium=Social\u0026utm_source=Mastodon\nhttps://amicale.net/system/media_attachments/files/113/488/006/233/143/852/original/6ceef2f37150be3a.jpg\n",
"sig": "2a0ac47960455b747f630e3345941aefc2f666490e54862eeca6915fa2c552a1513c84ab09fba214c6a3ddfff203993610823c564ed57180b2e54058ab645b12"
}
